Long Term Administration of Inhaled Mannitol in Cystic Fibrosis - A Safety and Efficacy Trial in Adult Cystic Fibrosis Subjects

Trial Profile

Long Term Administration of Inhaled Mannitol in Cystic Fibrosis - A Safety and Efficacy Trial in Adult Cystic Fibrosis Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Mannitol (Primary)
  • Indications Cystic fibrosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Pharmaxis
  • Most Recent Events

    • 13 Jun 2017 Status changed from active, no longer recruiting to completed, according to a Pharmaxis media release.
    • 13 Jun 2017 According to a Pharmaxis media release, additional data from the trial will be presented at the North American Cystic Fibrosis Conference in November, 2017.
    • 13 Jun 2017 According to a Pharmaxis media release, based on the results from this study, the company is expecting a resubmission of the Bronchitol New Drug Application to the FDA in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top